You are viewing: Asia Pacific Humanized Mouse and Rat Model Market analysis

The Asia Pacific Humanized Mouse and Rat Model Market was valued at $43.5 Million in 2025 and projected to reach to $66.4 Million by 2030, representing a compound annual growth rate of 8.9%. The Asia Pacific humanized mouse and rat model market is poised for sustained growth through 2030, driven by escalating pharmaceutical development activities and modernization of research infrastructure across the region.

Asia Pacific Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Humanized Mouse and Rat Model Market Trends and Insights

  • Asia Pacific's growth trajectory reflects increasing investment in preclinical research infrastructure, rising pharmaceutical development activities, and expanding biotechnology sectors across the region.
  • The 8.9% compound annual growth rate in Asia Pacific outpaces global trends, driven by growing adoption of advanced animal models in drug discovery and development. Asia Pacific's market expansion is underpinned by strengthening regulatory frameworks, increased R&D spending by both domestic and multinational pharmaceutical companies, and rising demand for personalized medicine research.
  • Key markets within Asia Pacific, including China, Japan, and South Korea, are establishing specialized research facilities and collaborating with international institutions to advance humanized model development.
  • Between 2025 and 2030, Asia Pacific is expected to capture an increasingly significant share of global preclinical research activities, positioning the region as a critical hub for next-generation drug development..

Key Market Statistics

  • CAGR (2025-2030) 8.9% CAGR
  • Market Size, 2025 ~USD 43.5 Million
  • Forecast, 2030 ~USD 66.4 Million
  • Geography Asia Pacific

Asia Pacific Humanized Mouse and Rat Model Market Overview

Rapid Market Expansion :

Asia Pacific's humanized mouse and rat model market is valued at $43.5 million in 2025, with strong momentum driving growth to $66.4 million by 2030, representing an 8.9% CAGR that outpaces the global average of 8.2%.

China's Market Leadership :

China dominates the Asia Pacific region with a market size of $29.2 million, reflecting substantial investments in pharmaceutical R&D and biotechnology infrastructure across major research hubs and contract research organizations.

Emerging Research Infrastructure :

Increasing establishment of preclinical research facilities and growing adoption of humanized animal models in drug development pipelines across Asia Pacific countries are accelerating market penetration and innovation.

Biotechnology Sector Growth :

Expanding biotechnology sectors in Japan ($19.7M), India ($5.7M), and South Korea ($4.1M) are driving demand for advanced preclinical testing models to support accelerated drug discovery and development timelines.

Asia Pacific Humanized Mouse and Rat Model Market Dynamics

  • Countries like China and Japan are investing heavily in preclinical research capabilities, while emerging markets in India and South Korea are rapidly adopting humanized animal models to support their growing biotech sectors. Regulatory support for alternative testing methods and increasing collaboration between academic institutions and pharmaceutical companies are further catalyzing market expansion.
  • The region's competitive labor costs, combined with improving research standards and growing venture capital funding, position Asia Pacific as an increasingly attractive hub for preclinical drug development and validation studies..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Asia Pacific's humanized mouse and rat model market is valued at $43.5 million in 2025, with projected growth to $66.4 million by 2030.
    • Asia Pacific demonstrates a CAGR of 8.9%, outpacing the global average and reflecting accelerating preclinical research demand.
    • Asia Pacific's growth is driven by increased pharmaceutical R&D investment, regulatory advancement, and expansion of biotechnology infrastructure.
    • Asia Pacific is emerging as a critical regional hub for drug discovery, attracting both domestic and international research collaborations.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    Asia Pacific Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    Target Audience

    • Pharmaceutical Companies : Pharmaceutical firms expanding preclinical research operations in Asia Pacific require detailed market intelligence to identify optimal locations, assess competitive dynamics, and plan investment in humanized model capabilities.
    • Contract Research Organizations (CROs) : CROs operating in Asia Pacific need market data to benchmark service offerings, identify growth markets, and strategically position humanized animal model services to support regional drug development pipelines.
    • Biotechnology Firms : Emerging biotech companies in Asia Pacific require market insights to understand preclinical testing options, supplier landscapes, and regional adoption trends to optimize drug development timelines and budgets.
    • Research Institutions : Academic and government research institutions across Asia Pacific use market data to justify infrastructure investments, secure funding for humanized model programs, and benchmark capabilities against regional peers.
    • Investors and Venture Capitalists : Investment firms targeting Asia Pacific biotech and pharmaceutical sectors require market forecasts and regional growth data to evaluate investment opportunities and assess portfolio company growth potential.

    Key Companies in the Asia Pacific Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Asia Pacific vs. other regions

    HowAsia Pacific compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 162.2 Million · 8.6% wtd CAGR ·
    Europe
    ~USD 101.4 Million · 8.7% wtd CAGR ·
    Latin America
    ~USD 5.7 Million · 7.4% wtd CAGR ·

    Countries within Asia Pacific - compare and drill down

    Country2025 size (native)
    ChinaUSD 29.2 Million
    JapanUSD 19.7 Million
    IndiaUSD 5.7 Million
    South KoreaUSD 4.1 Million
    AustraliaUSD 2.5 Million
    Rest Of Asia PacificUSD 5.1 Million

    Country market size visualization

    China
    USD 29.2 Million
    Japan
    USD 19.7 Million
    India
    USD 5.7 Million
    South Korea
    USD 4.1 Million
    Australia
    USD 2.5 Million
    Rest Of Asia Pacific
    USD 5.1 Million

    Reasons to Buy this Report

    • Regional Market Segmentation : Gain detailed insights into country-specific market dynamics across China, Japan, India, South Korea, and Australia with granular data on market sizes, growth trajectories, and competitive landscapes unique to Asia Pacific.
    • Growth Opportunity Identification : Identify high-potential markets and emerging opportunities within Asia Pacific where humanized model adoption is accelerating, enabling strategic market entry and expansion planning for pharmaceutical and biotech companies.
    • Competitive Intelligence : Understand regional competitive positioning, key players, and market consolidation trends specific to Asia Pacific to inform partnership strategies, acquisitions, and competitive differentiation initiatives.
    • Investment Decision Support : Access comprehensive forecasts and market sizing data for Asia Pacific to support capital allocation decisions, R&D investment prioritization, and facility expansion planning in high-growth regional markets.
    • Regulatory and Infrastructure Insights : Understand Asia Pacific-specific regulatory frameworks, research infrastructure development, and government support mechanisms that influence market dynamics and create localized business opportunities.

    Frequently asked questions

    What is the current market size of humanized mouse and rat models in Asia Pacific?

    The Asia Pacific humanized mouse and rat model market was valued at $43.5 million in 2025 and is expected to grow to $66.4 million by 2030.

    What is the projected growth rate for Asia Pacific's humanized mouse and rat model market?

    Asia Pacific's market is projected to grow at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2030.

    Which countries in Asia Pacific are driving market growth?

    Key markets in Asia Pacific include China, Japan, and South Korea, which are investing heavily in preclinical research infrastructure and biotechnology development.

    What factors are accelerating humanized model adoption in Asia Pacific?

    Asia Pacific's growth is driven by increased pharmaceutical R&D spending, strengthening regulatory frameworks, rising demand for personalized medicine research, and international research collaborations.

    How does Asia Pacific's growth compare to global market trends?

    Asia Pacific's 8.9% CAGR outpaces the global average of 8.2%, indicating the region is becoming an increasingly important center for preclinical research and drug development.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status